High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

MLA

Romaguera, Jorge E., et al. “High Rate of Durable Remissions after Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma with Rituximab plus Hyper-CVAD Alternating with Rituximab plus High-Dose Methotrexate and Cytarabine.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 23, no. 28, Oct. 2005, pp. 7013–23. EBSCOhost, https://doi.org/10.1200/JCO.2005.01.1825.

APA

Romaguera, J. E., Fayad, L., Rodriguez, M. A., Broglio, K. R., Hagemeister, F. B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Goy, A., Sarris, A. H., Dang, N. H., Wang, M., Beasley, V., Medeiros, L. J., Katz, R. L., Gagneja, H., Samuels, B. I., Smith, T. L., & Cabanillas, F. F. (2005). High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 23(28), 7013–7023. https://doi.org/10.1200/JCO.2005.01.1825

Chicago

Romaguera, Jorge E, Luis Fayad, Maria A Rodriguez, Kristine R Broglio, Frederick B Hagemeister, Barbara Pro, Peter McLaughlin, et al. 2005. “High Rate of Durable Remissions after Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma with Rituximab plus Hyper-CVAD Alternating with Rituximab plus High-Dose Methotrexate and Cytarabine.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 23 (28): 7013–23. doi:10.1200/JCO.2005.01.1825.